Lessons from irritable bowel syndrome: potential for understanding and managing post-COVID

Area of Science:

• Gastroenterology
• Infectious Diseases
• Immunology

Background:

• Post-COVID presents persistent symptoms after SARS-CoV-2 infection, posing a significant medical challenge.
• Post-infectious Irritable Bowel Syndrome (PI-IBS) serves as a potential model due to shared characteristics with post-COVID conditions.
• Both are functional disorders triggered by infection, exhibiting multifactorial causes and lacking specific biomarkers.

Purpose of the Study:

• To explore the parallels between PI-IBS and post-COVID conditions.
• To identify potential therapeutic strategies for post-COVID sequelae by examining IBS management.
• To assess the likelihood of rapid treatment development for post-COVID based on IBS research.

Main Methods:

• Comparative analysis of clinical features and etiological factors of post-COVID and PI-IBS.
• Review of existing therapeutic approaches for Irritable Bowel Syndrome (IBS).
• Examination of challenges in diagnosis and treatment development for functional disorders.

Main Results:

• Significant overlap exists in symptom variability, comorbidities, and diagnostic difficulties between post-COVID and PI-IBS.
• Stigmatization of these functional disorders complicates diagnosis and patient care.
• Decades of research in IBS drug development suggest potential delays in effective post-COVID treatments.

Conclusions:

• Understanding PI-IBS can inform the management of post-COVID long-term sequelae.
• The complex nature and diagnostic challenges of these functional disorders require further investigation.
• Rapid therapeutic breakthroughs for post-COVID may be unlikely given historical challenges in IBS treatment development.